+

WO2003052064A2 - Lignees de cellules clonales de myelomes utilisables pour la production de proteines dans un milieu defini chimiquement - Google Patents

Lignees de cellules clonales de myelomes utilisables pour la production de proteines dans un milieu defini chimiquement Download PDF

Info

Publication number
WO2003052064A2
WO2003052064A2 PCT/US2002/039496 US0239496W WO03052064A2 WO 2003052064 A2 WO2003052064 A2 WO 2003052064A2 US 0239496 W US0239496 W US 0239496W WO 03052064 A2 WO03052064 A2 WO 03052064A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
protein
cells
cell line
group
Prior art date
Application number
PCT/US2002/039496
Other languages
English (en)
Other versions
WO2003052064A3 (fr
Inventor
Chichang Lee
Celia Ly
Gordon Moore
Edward Savino
Original Assignee
Centocor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc. filed Critical Centocor Inc.
Priority to JP2003552931A priority Critical patent/JP2005512538A/ja
Priority to CA002470026A priority patent/CA2470026A1/fr
Priority to AU2002362130A priority patent/AU2002362130A1/en
Priority to EP02797264A priority patent/EP1490481A4/fr
Publication of WO2003052064A2 publication Critical patent/WO2003052064A2/fr
Publication of WO2003052064A3 publication Critical patent/WO2003052064A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Definitions

  • the present invention relates to cells, cell lines, and cell cultures useful in recombinant DNA technologies and for the production of proteins in cell culture, and further relates to clonal myeloma cell lines capable of growing in chemically defined media.
  • serum contains many components that have not been fully identified nor their role or mechanism of action determined.
  • serum will differ from batch to batch, possibly requiring testing to determine levels of the various components and their effects on cells.
  • serum might possibly be contaminated with microorganisms such as viruses, mycoplasma and perhaps prions, some of which may be harmless but nonetheless represent an additional unknown factor.
  • BSE Bovine Spongiform Encephalopathy
  • the present invention relates to cells, cell lines, and cell cultures useful in recombinant DNA technologies and for the production of proteins in cell culture.
  • the present invention relates to clonal myeloma cell lines or any cell lines derived therefrom that are capable of growing continuously in a chemically defined medium; growing to high cell density in a chemically defined medium; remaining viable after cryopreservation in the absence of serum; and detectably expressing recombinant proteins following genetic manipulation and/or subsequent culture in a chemically defined medium.
  • the expression of proteins is accomplished by manipulating the cells, cell lines, and cell cultures to express at least one protein in detectable amount.
  • the manipulation step may be accomplished by introducing a nucleic acid encoding at least one protein into the cells, cell lines, and cell cultures of the present invention.
  • the nucleic acid encoding at least one protein may be introduced by one of several methods including, but not limited to, electroporation, lipofection, calcium phosphate precipitation, polyethylene glycol precipitation, sonication, transfection, transduction, transformation, and viral infection.
  • the cells, cell lines, and cell cultures of the present invention are manipulated to express at least one desired protein in detectable amounts by inducing transcription and translation of a nucleic acid encoding at least one protein when such nucleic acid already exists in the cells, cell lines, and cell cultures.
  • the protein expressed in the cells, cell lines, and cell cultures of the present invention is a diagnostic protein.
  • the protein may be a therapeutic protein.
  • the diagnostic or therapeutic protein may be an immunoglobulin, a cytokine, an integrin, an antigen, a growth factor, a receptor or fusion protein thereof, any fragment thereof, or any structural or functional analog thereof.
  • the diagnostic or therapeutic protein may also be a cell cycle protein, a hormone, a neurotransmitter, a blood protein, an antimicrobial, a receptor or fusion protein thereof, any fragment thereof, or any structural or functional analog thereof.
  • the cells, cell lines, and cell cultures of the present invention may produce an irnmunoglobulin or fragment thereof derived from a rodent or a primate. More specficially, the --m unoglobulin or fragment thereof may be derived from a mouse or a human. Alternatively, the immunoglobulin or fragment thereof may be chimeric or engineered. Indeed, the present invention further contemplates cells, cell lines, and cell cultures that produce an immunoglobulin or fragment thereof which is humanized, CDR grafted, phage displayed, transgenic mouse-produced, optimized, mutagenized, randomized or recombined.
  • the cells, cell lines, and cell cultures of the present invention may produce an immunoglobulin or fragment thereof including, but not limited to, IgGl, IgG2, IgG3, IgG4, IgAl, IgA2; slgA, IgD, IgE, and any structural or functional analog thereof.
  • the immunoglobuUn expressed in the cells, cell lines, and cell cultures of the present invention is infliximab.
  • the immunoglobulin may be rTNV148B.
  • the immunoglobulin fragment produced by the cells, cell lines, and cell cultures of the present invention may include, but is not limited to, F(ab') , Fab', Fab, Fc, Facb, pFc', Fd, Fv, and any structural or functional analog thereof.
  • the immunoglobuhn fragment is abciximab.
  • the present invention further provides cells, cell lines, and cell cultures that express an immunoglobulin or fragment thereof which binds an antigen, a cytokine, an integrin, an antigen, a growth factor, a cell cycle protein, a hormone, a neurotransmitter, a receptor or fusion protein thereof, a blood protein, an antimicrobial, any fragment thereof, and any structural or functional analog of any of the foregoing.
  • the cells, cell lines, and cell cultures produce an integrin.
  • integrins contemplated by the present invention include, but are not limited to, l, ⁇ 2, ⁇ 3, ⁇ 4, ⁇ 5, ⁇ 6, al, ⁇ 8, 9, ⁇ D, ⁇ L, ⁇ M, ⁇ V, ⁇ X, odlb, ⁇ lELb, ⁇ l, ⁇ 2, ⁇ 3, ⁇ 4, ⁇ 5, ⁇ 6, ⁇ 7, ⁇ 8, ⁇ l ⁇ l, ⁇ 2 ⁇ l, ⁇ 3 ⁇ l, ⁇ 4 ⁇ l, ⁇ 5 ⁇ l, ⁇ l, ⁇ 7 ⁇ l, ⁇ 8 ⁇ l, ⁇ 9 ⁇ l, ⁇ 4 ⁇ 7, ⁇ 6 ⁇ 4, ⁇ D ⁇ 2, ⁇ L ⁇ 2, ⁇ M ⁇ 2, ⁇ V ⁇ l, ⁇ V ⁇ 3, ⁇ V ⁇ 5, ⁇ V ⁇ 6, ⁇ V ⁇ 8, ⁇ X ⁇ 2, ⁇ llb ⁇ 3, ⁇ IELb ⁇ 7, and any structural or functional analog
  • the recombinant protein expressed by the cells, cell lines, and cell cultures of the present invention is an antigen.
  • the antigen may be derived from a number of sources including, but not limited to, a bacterium, a virus, a blood protein, a cancer cell marker, a prion, a fungus, and any structural or functional analog thereof.
  • the cells, cell lines, and cell cultures of the present invention may detectably express a growth factor.
  • growth factors contemplated by the present invention include, but are not limited to, a human growth factor, a platelet derived growth factor, an epidermal growth factor, a fibroblast growth factor, a nerve growth factor, a human chorionic gonadotropin, an erythrpoeitin, an activin, an inhibin, a bone morphogenic protein, a transforming growth factor, an insulin-like growth factor, and any structural or functional analog thereof.
  • the cells, cell lines, and cell cultures of the present invention produce a recombinant cell cycle protein.
  • Such cell cycle proteins include, but are not limited to, a cyclin, a cyclin-dependent kinase, a tumor suppressor gene, a caspase protein, a Bcl-2, a p70 S6 kinase, an anaphase-promoting complex, a S- phase promoting factor, a M-phase promoting factor, and any structural or functional analog thereof.
  • the present invention further provides cells, cell lines, and cell cultures that express a cytokine.
  • cytokines contemplated by the present invention include, but are not limited to, an interleukin, an interferon, a colony stimulating factor, a tumor necrosis factor, an adhesion molecule, an angiogenin, an annexin, a chemokine, and any structural or functional analog thereof.
  • the recombinant protein expressed by the cells, cell lines, and cell cultures of the present invention is a growth hormone.
  • the growth hormone may include, but is not limited to, a human growth hormone, a growth hormone, a prolactin, a follicle stimulating hormone, a human chorionic gonadotrophin, a leuteinizing hormone, a thyroid stimulating hormone, a parathyroid hormone, an estrogen, a progesterone, a testosterone, an insulin, a pfoinsulin, and any structural or functional analog thereof.
  • the present invention further relates to the expression of neurotransmitters using the cells, cell lines, and cell cultures taught herein.
  • neurotransmitters include, but are not limited to, an endorphin, a coricotropin releasing hormone, an adrenocorticotropic hormone, a vaseopressin, a giractide, a N- acytlaspartylglutamate, a peptide neurotransmitter derived from pre-opiomelanocortin, any antagonists thereof, and any agonists thereof.
  • the cells, cell lines, and cell cultures of the present invention are manipulated to produce a receptor or fusion protein.
  • the receptor or fusion protein may be, but is not limited to, an interleukin-1, an interleukin-12, a tumor necrosis factor, an erythropoeitin, a tissue plasminogen activator, a thrombopoetin, and any structural or functional analog thereof.
  • recombinant blood proteins may be expressed in the cells, cell lines, and cell cultures of the present invention.
  • recombinant proteins include, but are not limited to, an erythropoeitin, a thrombopoeitin, a tissue plasminogen activator, a fibrinogen, a hemoglobin, a transferrin, an albumin, a protein c, and any structural or functional analog thereof.
  • the cells, cell lines, and cell cultures of the present invention express tissue plasminogen activator.
  • the cells, cell lines and cell cultures of the present invention produce a recombinant antimicrobial agent.
  • antimicrobial agents contemplated by the present invention include, for example, a beta-lactam, an aminoglycoside, a polypeptide antibiotic, and any structural or functional analog thereof.
  • the cells, cell lines, and cell cultures of the present invention produce recombinant proteins at about 0.01 mg/L to about 10,000 mg/L of culture medium. In another embodiment, the cells, cell lines, and cell cultures of the present invention produce recombinant proteins at a level of about 0.1 pg/cell/day to about 100 ng/cell/day.
  • the present invention further provides methods for producing at least one protein from a cultured cell.
  • cells of the present invention that express at least one desired protein are cultured in a chemically defined medium and the proteins are isolated from the chemically defined medium or from the cells themselves.
  • the present invention further relates to recombinant proteins obtained by this method.
  • the present invention also provides methods for identifying cell lines capable of growing continuously in a chemically defined medium.
  • cells from one type of cell line, which are not known to grow in a chemically defined medium are cultured in the chemically defined medium and spontaneous mutant cells that are capable of growing in the chemically defined medium are selected.
  • the present invention relates to at least one cell line obtained according to this method.
  • the present invention further relates to business methods where the cells, cell lines, cell cultures, and recombinant proteins obtained therefrom are provided to customers.
  • a customer is provided with a cell line of the present invention.
  • a customer is provided with a recombinant protein derived from a cell line of the present invention.
  • Figure la depicts cell line C463A post-thaw viability at 0 hours and 24 hours.
  • Figure lb is a graph depicting growth profiles of C463 A grown in both Sigma® Serum and Protein-Free Medium (a CD medium) and CD-Hybridoma medium (a CD medium) following freeze/thaw in CD-Hybridoma medium with 10% DMSO.
  • Figure lb shows the results of a growth profile of Sp 2/0 parental cells grown in CD-Hybridoma medium following freeze/thaw in IMDM, 20% FBS.
  • Figure 2 is a graph showing the growth profile of C463A semi-batch culture in CD-Hyrbidoma medium versus the growth profile of Sp 2/0 semi-batch culture in CD- Hybridoma medium. Total (TC) and viable cell (VC) densities are indicated.
  • Figure 3 is a graph illustrating the growth profile of C463A semi-batch culture in
  • CD-Hybridoma medium versus the growth profile of Sp 2/ o semi-batch culture in IMDM, 5% FBS (a chemically undefined medium).
  • Total cell (TC) and viable cell (VC) densities for days 3-7 are indicated.
  • Figure 4 presents four graphs that illustrate the growth profiles of cell line C524A in both IMDM, 5% FBS and CD-Hybridoma medium versus the growth profile of C466D in IMDM, 5% FBS.
  • Figure 4a depicts the percent viability over time for cells grown in spinner flasks.
  • Figure 4b illustrates viable cell density over time of cells grown in spinner flasks.
  • Figure 4c shows total cell density over time of cells grown in spinner flasks.
  • Figure 4d portrays IgG titer over time for cells grown in spinner flasks.
  • Figure 5 contains four graphs that compare the growth profile of C524A in both IMDM, 5% FBS and CD-Hybridoma medium versus the growth profile of C466D in IMDM, 5% FBS.
  • Figure 4a depicts the percent viability over time for cells grown in spinner flasks.
  • Figure 4b illustrates viable cell density over time of cells grown in spinner flas
  • Figure 5a illustrates the percent viability over time for cells grown in spinner flasks.
  • Figure 5b shows viable cell density over time of cells grown in spinner flasks.
  • Figure 5c portrays total cell density over time of cells grown in spinner flasks.
  • Figure 5d depicts IgG titer over time for cells grown in spinner flasks.
  • Figure 6 presents four graphs that represent data generated during an 11-passage stability study of C524A grown in both CDM medium and CD-Hybridoma medium.
  • Figure 6a shows the percent viability over time for cells grown in spinner flasks.
  • Figure 6b portrays mean doubting times over time of cells grown in spinner flasks.
  • Figure 6c depicts total cell density over time of cells grown in spinner flasks.
  • Figure 6d illustrates IgG titer over time for cells grown in spinner flasks.
  • Figure 7 contains four graphs that compare the growth profile of C524A in CDM medium with the growth profile of C524A in CD-Hybridoma medium after an 11-passage stability study.
  • Figure 7a portrays the percent viability over time for cells grown in spinner flasks.
  • Figure 7b depicts viable cell density over time of cells grown in spinner flasks.
  • Figure 7c illustrates total cell density over time of cells grown in spinner flasks.
  • Figure 7d shows IgG titer over time for cells grown in spinner flasks.
  • DETAILED DESCRIPTION OF THE INVENTION It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
  • the present invention relates to clonal myeloma cell lines that have the ability to grow continuously in CD media.
  • These clonal myeloma cell lines may derived from any number of commercially available myeloma cell tines, including, but not limited to, Sp 2/0 -Agl4 (American Type Culture Collection (“ATCC”), Manassas, Va., ATCC CRL No. 1851); P3X63Ag8.653 (ATCC CRL No. 1580); RPMI 8226 (ATCC CRL No. 155); and NSO (European Collection of Cell Cultures ("ECACC”), Salisbury, Wiltshire, U.K., ECACC No. 85110503).
  • Sp 2/0 -Agl4 American Type Culture Collection
  • P3X63Ag8.653 ATCC CRL No. 1580
  • RPMI 8226 ATCC CRL No. 155
  • NSO European Collection of Cell Cultures
  • myeloma cell lines are available from cell culture depositories such as ATCC; ECACC; Istituto Zooprofilatticosperimentale (“IZSBS”), Brescia, Italy; Human and Animal Cell Cultures (“DSMZ”), Braunschweig, F.R.G.; and Interlab Cell Line Collection (“ICLC”), Genova, Italy.
  • the clonal myeloma cell line is a spontaneous mutant cloned from a Sp 2/0 -Agl4 (“Sp /o”) cell bank in CD media.
  • the clonal myeloma cell line is designated C463A.
  • C463A Characterization of C463A revealed that the cell line has a number of unique growth characteristics not associated with parental Sp 2/ o cells. For example, C463A may be frozen and thawed in the absence of serum, a necessary cryopreservation agent for Sp? / o parental cell lines. In addition, unlike parental lines, C463A can grow to high cell density in CD media. Further characterization demonstrated that C463A grown in CD media exhibits growth parameters, including viable cell density and doubting time, that are similar or superior to those observed when cells are maintained in growth medium supplemented with serum.
  • CD media as used in the present invention, comprises growth media that are devoid of any components of animal origin, including serum, serum proteins, hydrolysates, or compounds of unknown composition. All components of CD media have a known chemical structure, resulting in the elimination of the batch-to-batch variability discussed previously.
  • the CD media used in the present invention may include, but is not limited to,
  • CD-Hybridoma a CD medium produced by Invitrogen Corp., Carlsbad, Cal. (Cat. No. 11279-023).
  • CD-Hybridoma medium was supplemented with 1 g L NaHC0 and L-Glutamine to final concentration of 6mM.
  • the present invention also contemplates the use of the chemically defined media, including "CDM medium,” described in Centocor's pending patent application, Serial No. 60/268,849, entitled “Chemically Defined Medium For Cultured Mammalian Cells,” which is expressly incorporated by reference.
  • protein-free media may still contain components of animal origin (e.g., cystine extracted from human hair) and/or undefined components of animal or plant origin (e.g., various hydrolysates which contribute low molecular weight peptides).
  • Protein-free media are a step closer to a defined formulation than serum-free media, which may contain discrete proteins or bulk protein fractions.
  • growth medium that is both serum-free and protein-free may be, in effect, a CD medium.
  • the present invention further contemplates the growth of C463A in Sigma® Serum and Protein-Free medium (Cat. No. S-8284), Sigma-Aldrich Corp., St. Louis, Mo., supplemented with 8 mM L-Glutamine for growth profiles.
  • the present invention comprises a spontaneous mutant derived from the myeloma cell line Sp 2/0 .
  • Sp /0 cells were seeded at a density of 40 cells/well in five 9 well cluster dishes with Sigma® Serum and Protein-Free Medium.
  • 37 wells contained viable colonies. Twenty of the thirty-seven colonies were expanded in 6-well plates.
  • Five primary candidate lines were visually identified and growth profiles at the T-75 stage were initiated.
  • Three secondary candidate cell lines were expanded and the remaining lines were pooled and frozen.
  • the clone designated 2D 11 was the most successful cell line, as indicated by its growth profile, and this line was subsequenfly designated C463A.
  • C463A was further expanded and analyzed for its ability to grow in various CD media.
  • C463A has the ability to sustain continuous growth in CD media.
  • C463A cultures were established in CD media (both CD-Hybridoma medium and Sigma® Serum and Protein-Free medium), routine maintenance performed (cell cultures split three times per week) and various growth parameters recorded. Table 1 shows the averages for several cell growth parameters over the course of ten consecutive passages (one month). Table 1.
  • C463A continuous culture in CD media were established in CD media (both CD-Hybridoma medium and Sigma® Serum and Protein-Free medium), routine maintenance performed (cell cultures split three times per week) and various growth parameters recorded. Table 1 shows the averages for several cell growth parameters over the course of ten consecutive passages (one month). Table 1.
  • C463A reached a total cell density comparable to that of Sp 2 /o parental cells grown in Iscove's Modified Dulbecco's Medium (IMDM), 5% Fetal Bovine Serum (FBS) (optimal medium).
  • IMDM Iscove's Modified Dulbecco's Medium
  • FBS Fetal Bovine Serum
  • percent viability and doubling time of C463A grown in CD media were also similar to that observed for Sp / 0 parental cells grown in optimal medium.
  • Further characterization of C463A indicated that the cell line has a number of unique growth characteristics not associated with the Sp 2/ o parental cells. For example, fetal bovine serum is not necessary when freezing, thawing, and establishing C463A culture.
  • C463A cells were grown to exponential growth phase in T-flasks or spinners. After spinning the cells at 800-1000 rpm, the cells were resuspended in 5 ml of CD-Hybridoma medium supplemented with 10% Dimethyl Sulfoxide (DMSO) at a density of 1 x 10 7 vc/ml (viable cells/ml). One milliliter aliquots were placed in cryovials and frozen overnight at -70°C. The vials were transferred to liquid nitrogen vapor phase within one week for long-term storage. After thawing in CD-Hybridoma medium, cell viabilities were measured at 0 and 24 hours, and cultures established in CD-Hybridoma medium.
  • DMSO Dimethyl Sulfoxide
  • Figure la indicates that post-thaw viabilities of C463A ranged between eighty-five to ninety percent, which is identical to Sp / o parental cells when frozen in the presence of 20% FBS (eight-five to ninety percent, data not shown).
  • Figure lb indicates that growth profiles of C463A cultures established in both Sigma® Serum and Protein-Free medium and CD-Hybridoma medium were typical in continuous culture conditions. Sp / o parental cells, however, grew poorly and were discontinued after the second passage in CD-Hybridoma medium.
  • FIG. 2 illustrates the growth profiles of C463A semi-batch culture in CD-Hybridoma medium versus the growth profile of Sp 2/ o semi-batch culture in CD- Hybridoma medium.
  • Semi-batch cultures provide the advantage of accumulating cells to high density by manually removing old medium and recycling total cells. Briefly, a semi-batch growth profile (seventy-five percent media changed daily 3 days post- inoculation) was initiated in CD-Hybridoma medium and growth parameters examined daily (days 3-7).
  • C463A growth and viability exceeded Sp 2 / 0 parental cells in the conditions described.
  • Viable and total cell densities of 3.27 x 10 6 vc/ml and 4.45 x 10 cells/ml were observed on day six for C463A, while control numbers were significantly less at 1 xlO 6 vc/ml and 1.35 x 10 6 cells/ml on day four.
  • C463A may be mampulated to stably express recombinant proteins.
  • cell line C463A is manipulated to produce recombinant proteins at a level of about 0.01 mg/L to about 10,000 mg/L of culture medium.
  • cell line C463A is manipulated to produce recombinant proteins at a level of about 0.1 pg/cell/day to about 100 ng/cell/day.
  • the present invention further relates to other clonal myeloma cell lines that have the ability to grow in CD media.
  • Such cell lines may be manipulated to stably express recombinant proteins by using methods known in the art or as taught herein.
  • the clonal myeloma cell lines of the present invention may be manipulated to produce recombinant proteins at a level of about 0.01 mg/L to about
  • the clonal myeloma cell lines of the present invention may be manipulated to produce recombinant proteins at a level of about 0.1 pg/cell/day to about 100 ng/cell/day.
  • nucleic acids encoding recombinant proteins may be accomplished via any one of a number of techniques well known in the art, including, but not limited to, electroporation, lipofection, calcium phosphate precipitation, polyethylene glycol precipitation, sonication, transfection, transduction, transformation, and viral infection. Indeed, molecular techniques are well known in the art. See SAMBROOKET AL., MOLECULAR CLONING: A LAB. MANUAL (2001); AUSBELET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (1995).
  • mammalian expression vectors may be used to express recombinant proteins in the cell culture taught herein.
  • Commercially available mammalian expression vectors that may be suitable for recombinant protein expression include, but are not limited to, pMAMneo (Clontech, Palo Alto, Cal.), pcDNA3 (Invitrogen, Carlsbad, Cal.), pMClneo (Stratagene, La JoUa, Cal.), pXTI (Stratagene, La JoUa, Cal.), pSG5 (Stratagene, La JoUa, Cal.), EBO-pSV2-neo (American Type Culture Collection ("ATCC”), Manassas, Va., ATCC No.
  • ATCC American Type Culture Collection
  • pBPV-l(8-2) ATCC No. 37110
  • pdBPV-MMTneo(342-12) ATCC No. 37224
  • pRSVgpt ATCC No. 37199
  • pRSVneo ATCC No. 37198
  • pSV2-dhfr ATCC No. 37146
  • pUCTag ATCC No. 37460
  • 17D35 ATCC No. 37565
  • the cells, cell lines, and cell cultures of the present invention may be used as a suitable hosts for a variety of recombinant proteins.
  • proteins include immunoglobulins, integrins, antigens, growth factors, cell cycle proteins, cytokines, hormones, neurotransmitters, receptor or fusion proteins thereof, blood proteins, antimicrobials, or fragments, or structural or functional analogs thereof.
  • immunoglobulins may be derived from human or non-human polyclonal or monoclonal antibodies.
  • these immunoglobulins may be recombinant and/or synthetic human, primate, rodent, mammalian, chimeric, humanized or CDR-grafted, antibodies and anti- idiotype antibodies thereto. These antibodies can also be produced in a variety of truncated forms in which various portions of antibodies are joined together using genetic engineering techniques.
  • an “antibody,” “antibody fragment,” “antibody variant,” “Fab,” and the like include any protein- or peptide- containing molecule that comprises at least a portion of an immunoglobulin molecule, such as but not limited to at least one CDR of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework region, or any portion thereof, which may be expressed in the cell culture of the present invention.
  • Such antibodies optionally further affect a specific ligand, such as but not limited to, where such antibody modulates, decreases, increases, antagonizes, agonizes, mitigates, alleviates, blocks, inhibits, abrogates and/or interferes with at least one target activity or binding, or with receptor activity or binding, in vitro, in situ and/or in vivo.
  • a specific ligand such as but not limited to, where such antibody modulates, decreases, increases, antagonizes, agonizes, mitigates, alleviates, blocks, inhibits, abrogates and/or interferes with at least one target activity or binding, or with receptor activity or binding, in vitro, in situ and/or in vivo.
  • such antibodies, or functional equivalents thereof may be "human,” such that they are substantially non-immunogenic in humans.
  • These antibodies may be prepared through any of the methodologies described herein, including the use of transgenic animals, genetically engineered to express human antibody genes. For example, immunized transgenic mice (xenomice) that express either fully human antibodies, or human variable regions have been described. See WO 96/34096.
  • the antibodies produced include fully human antibodies and can be obtained from the animal directly (e.g., from serum), or from immortalized B-cells derived from the animal, or from the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly or modified to obtain analogs of antibodies such as, for example, Fab or single chain Fv molecules. Id. These genes are then introduced into the cells, cell lines, and cell cultures of the present invention by methods known in the art, or as taught herein.
  • antibody is further intended to encompass antibodies, digestion fragments, specified portions and variants thereof, including antibody mimetics or comprising portions of antibodies that mimic the structure and/or function of an antibody or specified fragment or portion thereof, including single chain antibodies and fragments thereof, that are expressed in the cell culture of the present invention.
  • the present invention thus encompasses antibody fragments capable of binding to a biological molecule (such as an antigen or receptor) or portions thereof, including but not limited to Fab (e.g., by papain digestion), Fab' (e.g., by pepsin digestion and partial reduction) and F(ab') 2 (e.g., by pepsin digestion), facb (e.g., by plasmin digestion), pFc' (e.g., by pepsin or plasmin digestion), Fd (e.g., by pepsin digestion, partial reduction and reaggregation), Fv or scFv (e.g., by molecular biology techniques) fragments. See, e.g., CURRENT PROTOCOLS IN IMMUNOLOGY, (Colligan et al, eds., John Wiley & Sons, Inc., N.Y., 1994-2001).
  • target-binding peptides may be produced by the cells, cell lines, and cell cultures disclosed herein.
  • target-binding peptides may be isolated from tissues and purified to homogeneity, or isolated from cells that contain the target- binding protein, and purified to homogeneity. Once isolated and purified, such target- binding peptides may be sequenced by well-known methods. From these amino acid sequences, DNA probes may be produced and used to obtain mRNA, from which cDNA can be made and cloned by known methods. Other well-known methods for producing cDNA are known in the art and may effectively be used.
  • any desired peptide can be isolated from any cell or tissue expressing such proteins using a cDNA probe such as the probe described above, isolating mRNA and transcribing the mRNA into cDNA. Thereafter, the protein can be produced by inserting the cDNA into an expression vector, such as a virus, plasmid, cosmid, or other vector, inserting the expression vector into a cell, proliferating the resulting cells, and isolating the expressed target-binding protein from the medium or from cell extract as described above. See, e.g., U.S. Patent No. 5,808,029.
  • an expression vector such as a virus, plasmid, cosmid, or other vector
  • recombinant peptides may be identified using various library screening techniques.
  • peptide library screening takes advantage of the fact that molecules of only "peptide" length (2 to 40 amino acids) can bind to the receptor protein of a given large protein ligand.
  • Such peptides may mimic the bioactivity of the large protein ligand ("peptide agonists") or, through competitive binding, inhibit the bioactivity of the large protein ligand ("peptide antagonists").
  • Phage display peptide libraries have emerged as a powerful method in identifying such peptide agonists and antagonists. In such libraries, random peptide sequences are displayed by fusion with coat proteins of filamentous phage.
  • the displayed peptides are affinity-eluted against an immobilized extracellular domain of an antigen or receptor.
  • the retained phages may be enriched by successive rounds of affinity purification and repropagation.
  • the best binding peptides may be sequenced to identify key residues within one or more structurally related families of peptides.
  • the peptide sequences may also suggest which residues may be safely replaced by alanine scanning or by mutagenesis at the DNA level. Mutagenesis libraries may be created and screened to further optimize the sequence of the best binders. See, e.g., WO 00/24782; WO 93/06213; U.S. Patent No. 6,090,382.
  • E. coli displays employ a peptide library fused to either the carboxyl terminus of the lac- repressor or the peptidoglycan-associated lipoprotein, and expressed in E. coli.
  • Ribosome display involves halting the translation of random RNAs prior to ribosome release, resulting in a library of polypeptides with their associated RNAs still attached.
  • RNA-peptide screening employs chemical linkage of peptides to RNA.
  • chemically derived peptide libraries have been developed in which peptides are immobilized on stable, non-biological materials, such as polyethylene rods or solvent- permeable resins.
  • Another chemically derived peptide library uses photolithography to scan peptides immobilized on glass slides. These methods of chemical-peptide screening may be advantageous because they allow use of D-amino acids and other unnatural analogues, as well as non-peptide elements. See WO 00/24782. Moreover, structural analysis of protein-protein interaction may also be used to suggest peptides that mimic the binding activity of large protein ligands. In such an analysis, the crystal structure may suggest the identity and relative orientation of critical residues of the large protein ligand, from which a peptide may be designed. These analytical methods may also be used to investigate the interaction between a receptor protein and peptides selected by phage display, which may suggest further modification of the peptides to increase binding affinity.
  • an embodiment of the present invention may include the production of one or more growth factors.
  • growth factors are hormones or cytokine proteins that bind to receptors on the cell surface, with the primary result of activating cellular proliferation and/or differentiation.
  • Many growth factors are quite versatile, stimulating cellular division in numerous different cell types; while others are specific to a particular cell-type.
  • Table 2 presents several factors, but is not intended to be comprehensive or complete, yet introduces some of the more commonly known factors and their principal activities.
  • Additional growth factors that may be produced in accordance with the present invention include insulin and proinsulin (U.S. Patent No. 4,431,740); Activin (Vale et al., 321 NATURE 776 (1986); Ling et al., 321 NATURE 779 (1986)); Inhibin (U.S. Patent Nos. 4,740,587; 4,737,578); and Bone Morphongenic Proteins (BMPs) (U.S. Patent No. 5,846,931; WOZNEY, CELLULAR & MOLECULAR BIOLOGY OF BONE 131-167 (1993)).
  • BMPs Bone Morphongenic Proteins
  • the present invention may be useful for the production of other cytokines.
  • cytokines Secreted primarily from leukocytes, cytokines stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells.
  • Cytokines that are secreted from lymphocytes are termed lymphokines, whereas those secreted by monocytes or macrophages are termed monokines.
  • lymphokines secreted from lymphocytes
  • monocytes or macrophages are termed monokines.
  • a large family of cytokines are produced by various cells of the body.
  • Many of the lymphokines are also known as interleukins (ILs), since they are not only secreted by leukocytes but also able to affect the cellular responses of leukocytes.
  • ILs interleukins
  • interleukins are growth factors targeted to cells of hematopoietic origin.
  • the list of identified interleukins grows continuously. See, e.g., U.S. Patent Nos. 6,174,995, 6,143,289; Sallusto et al., 18 ANNU. REV. IMMUNOL. 593 (2000); Kunkel et al., 59 J. LEUKOCYTE BIOL. 81 (1996).
  • Additional growth factor/cytokines encompassed in the present invention include pituitary hormones such as human growth hormone (HGH), follicle stimulating hormones (FSH, FSH ⁇ , and FSH ⁇ ), Human Chorionic Gonadotrophins (HCG, HCG oc, HCG ⁇ ), uFSH (urofollitropin), Gonatropin releasing hormone (GRH), Growth Hormone (GH), leuteinizing hormones (LH, LH oc, LH ⁇ ), somatostatin, prolactin, thyrotropin (TSH, TSH , TSH ⁇ ), thyrotropin releasing hormone (TRH), parathyroid hormones, estrogens, progesterones, testosterones, or structural or functional analog thereof. All of these proteins and peptides are known in the art.
  • the cytokine family also includes tumor necrosis factors, colony stimulating factors, and interferons. See, e.g., Cosman, 7 BLOOD CELL BIOCHEM. (Whetten et al., eds., Plenum Press, New York, 1996); Grass et al., 85 BLOOD 3378 (1995); Beutler et al., 7 ANNU. REV. IMMUNOL. 625 (1989); Aggarwal et al., 260 J. BIOL. CHEM. 2345 (1985); Pennica et al., 312 NATURE 724 (1984); R & D Systems, CYTOKINE MINI- REVIEWS, at http://www.rndsystems.com.
  • cytokines of interest that may be produced by the cells, cell lines, and cell cultures of the present invention described herein include adhesion molecules (R & D Systems, ADHESION MOLECULES I (1996), at http://www.rndsystems.com); angiogenin (U.S. Patent No. 4,721,672; Moener et al., 226 EUR. J. BIOCHEM. 483 (1994)); annexin V (Cookson et al., 20 GENOMICS 463 (1994); Grandmann et al., 85 PNAS 3708 (1988); U.S. Patent No. 5,767,247); caspases (U.S. Patent No.
  • the present invention may also be used to produce recombinant forms of blood proteins, a generic name for a vast group of proteins generally circulating in blood plasma, and important for regulating coagulation and clot dissolution. See, e.g., Haematologic Technologies, Inc., HTI CATALOG, at www.haemtech.com.
  • Table 4 introduces, in a non-limiting fashion, some of the blood proteins contemplated by the present invention.
  • Table 4 Blood Proteins
  • Fibrinogen Plasma fibrinogen a large glycoprotein, FURLAN, FIBRINOGEN, IN HUMAN disulfide linked dimer made of 3 pairs of PROTEIN DATA, (Haeberli, ed., VCH non-identical chains (Aa, Bb and g), Publishers, N.Y.,1995); DOOL ⁇ TLE, in made in liver.
  • Aa has N-terminal peptide HAEMOSTASIS & THROMBOSIS, 491-513 (fibrinopeptide A (FPA), factor Xllla (3rd ed., Bloom et al., eds., Churchill crosslinking sites, and 2 phosphorylation Livingstone, 1994); HANTGAN ET AL., in sites.
  • Bb has fibrinopeptide B (FPB), 1 HAEMOSTASIS & THROMBOSIS 269-89 of 3 N-linked carbohydrate moieties, (2 nd ed., Forbes et al conflict eds., Churchill and an N-terminal pyroglutamic acid. Livingstone, 1991).
  • the g chain contains the other N-linked glycos. site, and factor Xllla cross- linking sites.
  • Two elongated subunits ((AaBbg) 2 ) align in an antiparallel way forming a trinodular arrangement of the 6 chains.
  • Nodes formed by disulfide rings between the 3 parallel chains.
  • Central node (n-disulfide knot, E domain) formed by N-termini of all 6 chains held together by 11 disulfide bonds, contains the 2 Ha-sensitive sites. Release of FPA by cleavage generates Fbn I, exposing a polymerization site on Aa chain. These sites bind to regions on the D domain of Fbn to form proto- fibrils.
  • Additional blood proteins contemplated herein include the following human serum proteins, which may also be placed in another category of protein (such as hormone or antigen): Actin, Actinin, Amyloid Serum P, Apolipoprotein E, B2- Microglobulin, C-Reactive Protein (CRP), Cholesterylester transfer protein (CETP), Complement C3B, Ceraplasmin, Creatine Kinase, Cystatin, Cytokeratin 8, Cytokeratin 14, Cytokeratin 18, Cytokeratin 19, Cytokeratin 20, Desmin, Desmocollin 3, FAS (CD95), Fatty Acid Binding Protein, Ferritin, Filamin, Glial Filament Acidic Protein, Glycogen Phosph ⁇ rylase Isoenzyme BB (GPBB), Haptoglobulin, Human Myoglobin, Myelin Basic Protein, Neurofilament, Placental Lactogen, Human SHBG, Human
  • Thyroid Peroxidase, Receptor Associated Protein Human Cardiac Troponin C, Human Cardiac Troponin I, Human Cardiac Troponin T, Human Skeletal Troponin I, Human Skeletal Troponin T, Vimentin, Vinculin, Transferrin Receptor, Prealbumin, Albumin, Alpha-1-Acid Glycoprotein, Alpha- 1-Antichymotrypsin, Alpha- 1-Antitrypsin, Alpha- Fetoprotein, Alpha- 1 -Microglobulin, Beta-2-microglobulin, C-Reactive Protein,
  • the cells, cell lines, and cell cultures of the present invention may also be used for the production of neurotransmitters, or functional portions thereof.
  • Neurotransmitters are compounds made by neurons and used by them to transmit signals to the other neurons or non-neuronal cells (e.g., skeletal muscle, myocardium, pineal glandular cells) that they innervate.
  • Neurotransmitters produce their effects by being released into synapses when their neuron of origin fires (i.e., becomes depolarized) and then attaching to receptors in the membrane of the post-synaptic cells. This causes changes in the fluxes of particular ions across that membrane, making cells more likely to become depolarized, if the neurotransmitter happens to be excitatory, or less likely if it is inhibitory.
  • Neurotransmitters can also produce their effects by modulating the production of other signal-transducing molecules ("second messengers") in the post-synaptic cells. See generally COOPER, BLOOM & ROTH, THE BIOCHEM. BASIS OF NEUROPHARMACOLOGY (7th Ed. Oxford Univ. Press, NYC, 1996); http://web.indstate.edu thcme/mwking/nerves.
  • second messengers signal-transducing molecules
  • Neurotransmitters contemplated in the present invention include, but are not limited to, endorphins (such as leu-enkephahn, morphiceptin, substance P), corticotropin releasing hormone, adrenocorticotropic hormone, vasopressin, giractide, peptide neurotransmitters derived from pre- opiomelanocortin, and N-acetylaspartylglutamate, the most prevalent and widely distributed peptide neurotransmitter in the mammalian nervous system. See Neale et al. 75 J. NEUROCHEM. 443-52 (2000).
  • IL-1 IL-1
  • TNF- ⁇ cytokines in the pathogenesis of rheumatoid arthritis
  • IL-1 and TNF- ⁇ act synergistically to induce each other, other cytokines, and COX-2.
  • IL-1 is a primary mediator of bone and cartilage destruction in rheumatoid arthritis patients
  • TNF- ⁇ appears to be the primary mediator of inflammation.
  • arecombinant protein produced by the cells, cell tines, and cell cultures of the present invention binds to tumor necrosis factor alpha (TNF ⁇ ), a pro-inflamatory cytokine.
  • TNF ⁇ tumor necrosis factor alpha
  • Anti- TNF ⁇ antibodies have shown great promise as therapeutics.
  • Infliximab provided commercially as REMICADE® by Centocor, Inc. (Malvern, Penn.) has been used for the treatment of several chronic autoimmune diseases such as Crohn's disease and rheumatoid arthritis. See Centocor's pending U.S. patent applications, Serial Nos. 09/920,137; 60/236,826; 60/223,369. See also Treacy, 19(4) HUM. EXP. TOXICOL. 226- 28 (2000); see also Chantry, 2(1) CURR. OPIN. ANTI-INFLAMMATORY
  • any exposed amino acids of the TNF ⁇ - binding moiety of the protein produced by the cell culture of the present invention are those with minimal antigenicity in humans, such as human or humanized amino acid sequences.
  • peptide identities may be generated by screening libraries, as described above, by grafting human amino acid sequences onto murine-derived paratopes (Siegel et al., 7(1) CYTOKINE 15-25 (1995); WO 92/11383) or monkey- derived paratopes (WO 93/02108), or by utilizing xenomice (WO 96/34096).
  • murine-derived anti-TNF ⁇ antibodies have exhibited efficacy. Saravolatz et al., 169(1) J. INFECT. DIS. 214-17 (1994).
  • the TNF ⁇ binding moiety of the protein produced in the cells, cell lines, and cell cultures of the present invention may be derived from the TNF ⁇ receptor.
  • Etanercept is a recombinant, soluble TNF ⁇ receptor molecule that is administered subcutaneously and binds to TNF ⁇ in the patient's serum, rendering it biologically inactive.
  • Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgGl.
  • the Fc component of etanercept contains the C H 2 domain, the Q ⁇ 3 domain and hinge region, but not the jl domain of IgGl.
  • Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons. Etanercept may be obtained as ENBRELTM, manufactured by Immunex Corp. (Seattle, Wash.). Etanercept may be efficacious in rheumatoid arthritis. Hughes et al., 15(6) BIODRUGS 379-93 (2001). Another form of human TNF receptor exists as well, identified as p55.
  • a second generation molecule was designed to remove the antigenic epitopes of TNFbp, and may be useful in treating patients with rheumatoid arthritis. Davis et al., Presented at ANN. EUROPEAN CONG. RHEUMATOLOGY, Nice, France (June 21- 24, 2000).
  • IL-1 receptor antagonist is a naturally occurring cytokine antagonist that demonstrates anti-inflammatory properties by balancing the destructive effects of IL-l ⁇ and IL-l ⁇ in rheumatoid arthritis but does not induce any intracellular response.
  • the cell culture may produce IL- lRa, or any structural or functional analog thereof.
  • IL-lRa Two structural variants of IL-lRa exist: a 17-kDa form that is secreted from monocytes, macrophages, neutrophils, and other cells (sIL-lRa) and an 18-kDa form that remains in the cytoplasm of keratinocytes and other epithelial cells, monocytes, and fibroblasts (icIL-lRa).
  • An additional 16-kDa intracellular isoform of IL-lRa exists in neutrophils, monocytes, and hepatic cells. Both of the major isoforms of IL-lRa are transcribed from the same gene through the use of alternative first exons.
  • IL-lRa The production of IL-lRa is stimulated by many substances including adherent IgG, other cytokines, and bacterial or viral components.
  • adherent IgG adherent IgG
  • other cytokines other cytokines
  • bacterial or viral components The tissue distribution of IL-lRa in mice indicates that sIL-lRa is found predominantly in peripheral blood cells, lungs, spleen, and liver, while icIL-lRa is found in large amounts in skin.
  • Studies in transgenic and knockout mice indicate that IL-lRa is important in host defense against endotoxin-induced injury.
  • IL-lRa is produced by hepatic cells with the characteristics of an acute phase protein. Endogenous IL-lRa is produced in human autoimmune and chronic inflammatory diseases.
  • IL-lRa is an important natural antiinflammatory protein in arthritis, colitis, and granulomatous pulmonary disease.
  • IL-lRa that may be produced by the cells, cell lines, and cell cultures described herein is a recombinant human version called interleukin-1 17.3 Kd met-ILlra, or Anakinra, produced by Amgen, (San Francisco, Cal.) under the name KINERETTM. Anakinra has also shown promise in clinical studies involving patients with rheumatoid arthritis. 65th ANN. SCI. MEETING OF AM. COLLEGE RHEUMATOLOGY (NOV. 12, 2001).
  • the protein produced by the cells, cell lines, and cell cultures of the present invention is interleukin 12 (IL-12) or an antagnoist thereof.
  • IL-12 is a heterodimeric cytokine consisting of glycosylated polypeptide chains of 35 and 40 kD which are disulfide bonded.
  • the cytokine is synthesized and secreted by antigen presenting cells, including dendritic cells, monocytes, macrophages, B cells, Langerhans cells and keratinocytes, as well as natural killer (NK) cells.
  • IL-12 mediates a variety of biological processes and has been referred to as NK cell stimulatory factor (NKSF), T-cell stimulating factor, cytotoxic T- lymphocyte maturation factor and EBV-transformed B-cell line factor. Curfs et al., 10 CLIN. MICRO. REV. 742-80 (1997).
  • Interleukin- 12 can bind to the IL-12 receptor expressed on the plasma membrane of cells (e.g., T cells, NK cell), thereby altering (e.g., initiating, preventing) biological processes.
  • the binding of IL-12 to the IL-12 receptor can stimulate the proliferation of pre-activated T cells and NK cells, enhance the cytolytic activity of cytotoxic T cells (CTL), NK cells and LAK (lymphokine activated killer) cells, induce production of gamma interferon (IFN ⁇ ) by T cells and NK cells and induce differentiation of naive ThO cells into Thl cells that produce IFN ⁇ and IL-2.
  • CTL cytotoxic T cells
  • LAK lymphokine activated killer
  • IL-12 is vital for the generation of cytolytic cells (e.g., NK, CTL) and for mounting a cellular immune response (e.g., a Thl cell mediated immune response).
  • cytolytic cells e.g., NK, CTL
  • a cellular immune response e.g., a Thl cell mediated immune response
  • IL-12 is critically important in the generation and regulation of both protective immunity (e.g., eradication of infections) and pathological immune responses (e.g., autoimmunity).
  • protective immunity e.g., eradication of infections
  • pathological immune responses e.g., autoimmunity
  • an immune response e.g., protective or pathogenic
  • the cells, cell lines, and cell cultures of the present invention produce an integrin.
  • Integrins have been implicated in the angiogenic process, by which tumor cells form new blood vessels that provide tumors with nutrients and oxygen, carry away waste products, and to act as conduits for the metastasis of tumor cells to distant sites. Gastl et al., 54 ONCOL. 177-84 (1997).
  • Integrins are heterodimeric transmembrane proteins that play critical roles in cell adhesion to the extracellular matrix (ECM) which, in turn, mediates cell survival, proliferation and migration through intracellular signaling.
  • ECM extracellular matrix
  • the heterodimeric integrins are comprise of an alpha subunit and a beta summit.
  • alpha subunits which include ⁇ l, ⁇ 2, ⁇ 3, ⁇ 4, ⁇ 5, ⁇ 6, ⁇ 7, ⁇ 8, ⁇ 9, ⁇ D, ⁇ L, ⁇ M, ⁇ V, ⁇ X, ⁇ llb, ⁇ lELb.
  • beta subunits which include ⁇ l, ⁇ 2, ⁇ 3, ⁇ 4, ⁇ 5, ⁇ 6, ⁇ 7, ⁇ 8.
  • Some of the integrin heterodimers include, but are not limited to, ⁇ l ⁇ l, ⁇ 2 ⁇ l, ⁇ 3 ⁇ l, ⁇ 4 ⁇ l, ⁇ 5 ⁇ l, ⁇ 6 ⁇ l, ⁇ 7 ⁇ l, ⁇ 8 ⁇ l, ⁇ 9 ⁇ l, ⁇ 4 ⁇ 7, ⁇ 6 ⁇ 4, ⁇ D ⁇ 2, ⁇ L ⁇ 2, ⁇ M ⁇ 2, ⁇ V ⁇ l, ⁇ V ⁇ 3, ⁇ V ⁇ 5, ⁇ V ⁇ 6, ⁇ V ⁇ 8, ⁇ X ⁇ 2, ⁇ llb ⁇ 3, ⁇ IELb ⁇ 7. See generally, Block et al., 13 STEM CELLS 135-145 (1995); Schwartz et al., 1(1) ANN. REV. CELL DEV. BIOL. 549- 599 (1995); Hynes, 69 CELL 11-25 (1992).
  • integrins that are expressed on the surface of activated endothelial cells regulate critical adhesive interactions with a variety of ECM proteins to regulate distinct biological events such as cell migration, proliferation and differentiation.
  • the closely related but distinct integrins aVb3 and aVb5 have been shown to mediate independent pathways in the angiogenic process.
  • An antibody generated against ⁇ V ⁇ 3 blocked basic fibroblast growth factor (bFGF) induced angiogenesis, whereas an antibody specific to ⁇ V ⁇ 5 inhibited vascular endothelial growth factor-induced (VEGF-induced) angiogenesis.
  • bFGF basic fibroblast growth factor
  • VEGF-induced vascular endothelial growth factor-induced
  • the cells, cell lines, and cell cultures produce a glycoprotein Ilb/IIIa receptor antagonist.
  • the final obligatory step in platelet aggregation is the binding of fibrinogen to an activated membrane-bound glycoprotein complex, GP Ilb/IIIa.
  • Platelet activators such as thrombin, collagen, epinephrine or ADP, are generated as an outgrowth of tissue damage.
  • GP Ilb/IIIa undergoes changes in conformation that results in exposure of occult binding sites for fibrinogen.
  • fibrinogen can potentially act as a hexavalent ligand to crossing GP Ilb/IIIa molecules on adjacent platelets.
  • a deficiency in either fibrinogen or GP Ilb/IIIa a prevents normal platelet aggregation regardless of the agonist used to activate the platelets. Since the binding of fibrinogen to its platelet receptor is an obligatory component of normal aggregation, GP Ilb/IIIa is an attractive target for an antithrombotic agent.
  • the monoclonal antibody 7E3 which blocks the GP Ilb/ ⁇ ia receptor, has been shown to be an effective therapy for the high risk angioplasty population. It is used as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy for the prevention of acute cardiac ischemic complications in patients at high risk for abrupt closure of the treated coronary vessel. Although 7E3 blocks both the Ilb/IIIa receptor and the ⁇ y ⁇ 3 receptor, its ability to inhibit platelet aggregation has been attributed to its function as a Ilb/IIIa receptor binding inhibitor.
  • the Ilb/IIIa receptor antagonist may be, but is not limited to, an antibody, a fragment of an antibody, a peptide, or an organic molecule.
  • the target-binding moiety may be derived from 7E3, an antibody with glycoprotein Ilb/IIIa receptor antagonist activity.
  • 7E3 is the parent antibody of c7E3, a F(ab') 2 fragment known as abciximab, known commercially as REOPRO®, produced by Centocor, Inc (Malvern, Perm.).
  • Abciximab binds and inhibits the adhesive receptors GPIIbTIIa and ov ⁇ 3 , leading to inhibition of platelet aggregation and thrombin generation, and the subsequent prevention of thrombus formation.
  • Patent Nos. 5,976,532; 5,877,006; 5,770,198; Coller, 78 THROM. HAEMOST. 730-35 (1997); JORDAN ET AL., in NEW THERAPEUTIC AGENTS IN THROMBOSIS & THROMBOLYSIS (Sasahara & Loscalzo, eds. Marcel Kekker, Inc. New York, 1997); JORDAN ET AL., in ADHESION RECEPTORS AS THERAPEUTIC TARGETS 281-305 (Horton, ed. CRC Press, New York, 1996).
  • the protein produced by the cells, cell lines, and cell cultures of the present invention may be a thrombolytic.
  • the thrombolytic may be tPA, or a functional variation thereof.
  • RETAVASE® produced by Centocor, Inc.
  • the cells, cell lines, and cell cultures of the present invention may also be used produce receptors, or fragments thereof, and activated receptors, i.e., recombinant peptides that mimic ligands associated with their corresponding receptors, or fragments thereof. These complexes may mimic activated receptors and thus affect a particular biological activity.
  • the receptor can be genetically re-engineered to adopt the activated conformation.
  • the thrombin-bound conformation of fibrinopeptide A exhibits a strand-turn-strand motif, with a ⁇ -turn centered at residues Glu-11 and Gly-12.
  • Molecular modeling analysis indicates that the published fibrinopeptide conformation cannot bind reasonably to thrombin, but that reorientation of two residues by alignment with bovine pancreatic trypsin inhibitor provides a good fit within the deep thrombin cleft and satisfies all of the experimental nuclear Overhauser effect data.
  • activated-receptor moieties concerns the peptido mimetics of the erythropoietin (Epo) receptor.
  • Epo erythropoietin
  • the Epo- bound, activated EpoR is a dimer. See, e.g., Constantinescu et al., 98 PNAS 4379-84 (2001). In its natural state, the first EpoR in the dimer binds Epo with a high affinity whereas the second EpoR molecule binds to the complex with a low affinity.
  • Bivalent anti-EpoR antibodies have been reported to activate EopR, probably by dimerization of the EpoR.
  • an embodiment of the present invention provides for a method of producing an activated EpoR mimetic using the disclosed cell culture system.
  • the cells, cell lines, and cell cultures may be used to produce antimicrobial agents or portions thereof, which include antibacterial agents, antivirals agents, antifungal agents, antimycobacterial agents, and antiparasitic agents.
  • Antibacterials include, but are not limited to, -lactam antibiotics (penicillin G, ampicillin, oxacillin), aminoglycosides (streptomycin, kanamycin,neomycin and gentamicin), and polypeptide antibiotics (colistin, polymyxin B).
  • Antimycobacterial agents that may be produced by the present cell culture include streptomycin.
  • the cells, cell lines, and cell cultures may be used to produce a cell cycle protein or a functionally active portion of a cell cycle protein.
  • cell cycle proteins are known in the art, and include cyclins, such as Gi cyclins, S-phase cyclins, M-phase cyclins, cyclin A, cyclin D and cyclin E; the cyclin-dependent kinases (CDKs), such as Gi CDKs, S-phase CDKs and M-phase CDKs, CDK2, CDK4 and CDK 6; and the tumor suppressor genes such as Rb and p53.
  • cyclins such as Gi cyclins, S-phase cyclins, M-phase cyclins, cyclin A, cyclin D and cyclin E
  • CDKs cyclin-dependent kinases
  • the tumor suppressor genes such as Rb and p53.
  • Cell cycle proteins also include those involved in apoptosis, such as Bcl-2 and caspase proteins; proteins associated with Cdc42 signaling, p70 S6 kinase and PAK regulation; and integrins, discussed elsewhere. Also included in the cell cycle proteins of the present invention are anaphase-promoting complex (APC) and other proteolytic enzymes.
  • the APC triggers the events leading to destruction of the cohesins and thus allowing sister chromatids to separate, and degrades the mitotic (M-phase) cyclins.
  • Cell cycle proteins also include pl3, p27, p34, p60, p80, histone HI, centrosomal proteins, lamins, and CDK inhibitors. Other relevant cell cycle proteins include S- phase promoting factor, M-phase promoting factor that activates APC. Kimball, Kimball's Biology Pages, at http://www.ultranet.com/ ⁇ jkimball/BiologyPages.
  • the cells, cell lines, and cell cultures of the present invention may also produce a particular antigen or portion thereof.
  • Antigens in a broad sense, may include any molecule to which an antibody, or functional fragment thereof, binds. Such antigens may be pathogen derived, and be associated with either MHC class I or MHC class II reactions. These antigens may be proteinaceous or include carbohydrates, such as polysaccharides, glycoproteins, or lipids. Carbohydrate and lipid antigens are present on cell surfaces of all types of cells, including normal human blood cells and foreign, bacterial cell walls or viral membranes. See SEARS, IMMUNOLOGY (W. H. Freeman & Co. and Sumanas, Inc., 1997), available on-line at http://www.whfreeman.com/immunology.
  • recombinant antigens may be derived from a pathogen, such as a viras, bacterium, mycoplasm, fungus, parasite, or from another foreign substance, such as a toxin.
  • bacterial antigens may include or be derived from Bacillus anthracis, Bacillus tetani, Bordetella pertusis; Brucella spp., Corynebacterium diphtheriae, Clostridium botulinum, Clostridium perfringens, Coxiella burnetii, Francisella tularensis, Mycobacterium leprae, Mycobacterium tuberculosis, Salmonella typhimurium, Streptocccus pneumoniae, Escherichia coli, Haemophilus influenzae, Shigella spp., Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningiditis, Treponema pal
  • Viruses and viral antigens that are within the scope of the current invention include, but are not limited to, HBeAg, Hepatitis B Core, Hepatitis B Surface Antigen, Cytomegaloviras B, HIV-1 gag, HIV-1 nef, HIV-1 env, HIV-1 gp41-l, HIV-1 p24, HIV-1 MN gpl20, HIV-2 env, HIV-2 gp 36, HCV Core, HCV NS4, HCV NS3, HCV p22 nucleocapsid, HPV LI capsid, HSV-1 gD, HSV-1 gG, HSV-2 gG, HSV-fl, Influenza A (H1N1), Influenza A (H3N2), Influenza B, Parainfluenza Viras Type 1, Epstein Barr virus capsid antigen, Epstein Barr virus, Poxviridae Variola major, Poxviridae Variola minor, Rotaviras, Rubella virus, Respiratory
  • toxins, toxoids, or antigenic portions of either may be produced by the cells, cell lines, and cell cultures presented herein. These include those recombinant forms of toxins produced natively by bacteria, such as diphteria toxin, tetanus toxin, botulin toxin and enterotoxin B and those produced natively by plants, such as Ricin toxin from the castor bean Ricinus cummunis.
  • Other toxins and toxoids that may be generated recombinantly include those derived from other plants, snakes, fish, frogs, spiders, scorpions, blue-green algae, fungi, and snails.
  • antigens that may be produced by the cells, cell lines, and cell cultures of the present invention may be those that serve as markers for particular cell types, or as targets for an agent interacting with that cell type.
  • HLA markers Human Leukocyte Antigens
  • MHC Class I and Class II the numerous CD markers useful for identifying T-cells and the physiological states thereof.
  • antigens may serve as "markers" for a particular disease or condition, or as targets of a therapeutic agent. Examples include, Prostate Specific Antigen, Pregnancy specific beta 1 glycoprotein (SP1), Carcinoembryonic Antigen (CEA), Thyroid Microsomal Antigen, and Urine Protein 1.
  • Antigens may include those defined as "self implicated in autoimmune diseases.
  • the present invention further relates to business methods where the cells, cell lines, cell cultures and recombinant proteins derived therefrom are provided to customers.
  • a customer is provided with the cells, cell lines, or cell cultures of the present invention.
  • a customer is provided with the cells, cell lines, or cell cultures cell line of the present invention that are transfected with an expression vector encoding a recombinant protein.
  • a customer is provided with a recombinant protein purified from the cells, cell lines, or cell cultures cell tine of the present invention.
  • Example 1 Transfection of cell line C463A with rTNV148B, a human antibody to Tumor Necrosis Factor Alpha (TNF ⁇ ), to create the C463A-derived rTNV148B- production cell line designated C524A.
  • TNF ⁇ Tumor Necrosis Factor Alpha
  • the cell line C463A was further tested as a suitable host for the expression of recombinant proteins.
  • This example describes the transfection and subsequent development of the C463A-derived rTNV148B production cell line designated C524A.
  • rTNV148B is a totally human monoclonal antibody directed against TNF ⁇ , the genes for which were obtained using hybridoma techniques and transgenic mice.
  • Transfection and Screening rTNV148B heavy chain expression vector, designated plasmid pl865 was linearized by digestion with Xhol and rTNV148B light chain expression vector, designated plasmid pl860, was linearized using Sail restriction enzyme.
  • the seven top-producing clones were subcloned to identify a higher-producing, more homogeneous cell line.
  • Ninety-six-well tissue culture dishes were seeded at 5 cells/ml and 20 cells/ml in IMDM, 5% FBS, 2mM glutamine and IX MHX. The cells were incubated for about 14 days until colonies were visible.
  • Cell supernatants from wells in which there was a single colony growing were assayed by ELISA, as described above.
  • the higher-producing colonies were transferred to 24-well tissue culture dishes and the supernatants from spent cultures were assayed by ELISA.
  • Eight clones were identified as the highest producers and these were subjected to a second round of subcloning in a manner identical to how the highest-producing first-round subclones were identified.
  • Table 6 shows the antibody production titers for selected cell lines. Titers represent the value determined by ELISA on spent 24-well supernatant in IMDM, 5% FBS. Significant improvement in titers was not observed in the first round of subclones as compared to the parents, except for the subclone of parental clone 1 that doubled in IgG titer. The second round of subcloning did not yield any substantial increase in titer. Six of the highest-producing second-round subclones were selected for further characterization. Accordingly, the six cultures were assigned clone numbers for easy tracking. Table 6 shows the tracking designations and cell hne codes of the six second- round subclones chosen for further characterization.
  • SFM8 media A chemically undefined medium. This serum-free but not protein-free medium comprises IMDM, Primatone® (Sheffield Prods., Hoffman Estates, 111.), Albumin, and Excyte® (Bayer, Kankakee, 111.).
  • IMDM 5% FBS medium (optimal growth medium): A chemically undefined medium. IMDM is available from, e.g., JRH Biosci. (Lenexa, Kan.), Cat. 51471. Fetal Bovine Serum is available from, e.g., Intergen Co. (Purchase, N.Y.), Cat. 1020-01, or HyClone (Logan, Utah), Cat. SH30071. 3. CDM medium: This CD medium is derived from SFM8 medium. CDM medium does not contain Primatone®, albumin, or Excyte®, all of which are present in SFM8 medium.
  • CDM medium (Primatone®, albumin and Excyte® deprived SFM8 medium) is then supplemented with a 2X final concentration of trace elements A (Mediatech, Herdon, Va., Cat. 99 182-C1, 1000X stock), a 2X final concentration of trace elements B (Mediatech, Cat. 99-175-C1, 1000X stock), a 2X final concentration of trace elements C (Mediatech, Cat. 99-176-C1, 1000X stock) and a IX final concentration of vitamins (Mediatech, Cat. 25-020-C1, 100X stock) to make the complete CDM medium.
  • the trace elements and vitamins do not contain components of animal origin.
  • CD-Hybridoma medium a CD medium produced by Invitrogen, Carlsbad, Cal. (Cat.11279-023). CD-Hybridoma medium was supplemented with 1 g/L of NaHC0 3 , and L-Glutamine to final concentrations of 6 mM.
  • C466D is another rTNV148B production cell line that is derived from mouse myeloma cells. C466D cells produce about 30 ⁇ g/ml IgG in
  • the six selected cultures were expanded in IMDM, 5% FBS. Two to three vials from each cell line were frozen as safe freezes before weaning into CD media. During the process of expansion and weaning, some T-flask cultures from each cell tine were set aside to overgrow until completely spent (12-14 days). IgG titers were determined by Nephlometry to evaluate each clone's capability to produce IgG.
  • Table 7 shows the IgG titers present in spent cultures from the six second-round subclones in various media at early stages of development. Based on IgG titers, Clones #2 through #4 were terminated from further development. The three remaining clones each produced over 100 ⁇ g/ml IgG in SFM8 medium. In IMDM, 5%FBS, however, only Clone #1 produced 90-100 ⁇ g/ml IgG compared to 30 ⁇ g/ml produced by C466D.
  • CD-Hybridoma medium CD-Hybridoma medium.
  • C524A, C525A and C526A cells showed no difficulty in growing in CD-Hybridoma medium and were quickly expanded to spinner flasks to make a RCB from C524A and C526A.
  • CD-Hybridoma cultures of C524A, C525A and C526A are shown above in Table 7.
  • batch culture type growth profiles were performed to compare these two cultures to C466D grown in IMDM, 5% FBS.
  • Duplicate cultures in 250 ml spinner flasks were seeded at a cell density of 2 x 10 5 vc/ml in IMDM, 5% FBS and 3 x 10 5 vc/ml in CD-Hybridoma medium. Each spinner flask contained 150 ml of medium and spinner speed was set at 60 rpm.
  • One 2.5-ml sample was collected from each spinner flask for daily cell counts and IgG titer. Cultures were terminated after viability dropped below twenty percent.
  • the data illustrated in Figure 4 indicate that C524A cultures grown in either
  • CD-Hybridoma medium or IMDM 5% FBS grew at least as well as C466D grown in IMDM, 5% FBS.
  • the total cell densities for all three cultures ranged from 2.2 x 10 6 cells/ml to 2.4 x 10 6 cells/ml ( Figure 4c), and total viable cell density ranged from 1.2 x 10 6 cells/ml (both C524A and C466D in IMDM, 5% FBS) to 2.2 x 10° cells/ml (C524A in CD-Hybridoma medium) ( Figure 4b).
  • C524A in IMDM, 5% FBS lasted longer than the other two, based on the days that viability stayed above twenty percent ( Figure 4a).
  • the final IgG titer of C524A in either CD-Hybridoma medium or IMDM, 5% FBS was around 80 ⁇ g/ml, compared to 30 ⁇ g/ml produced by C466D in IMDM, 5% FBS.
  • the transfer of C524A, C525A and C526A into CDM medium was more difficult than the transfer into CD-Hybridoma medium (C466D failed to transfer into CDM medium). The cells did not grow for the first 2-3 passages and viability dropped to about forty percent or less.
  • the surviving cells were then harvested and seeded into IMDM, 5% FBS for a few passages until viability was restored to about ninety percent.
  • the rescued cells were then washed and seeded into CDM medium again. In most cases, this selection-rescue-selection process was repeated two to three times before cultures with good viability (>80%) and 30 to 40 hour doubling times were obtained.
  • IgG titers of C525A and C526A in CDM medium were only about 60-70 ⁇ g/ml compared to 130 ⁇ g/ml produced by C524A in the same medium. Further characterization of C524A, C525A, and C526A revealed C524A to be the superior production cell line.
  • Figure 6 shows that the doubting times of all four cell cultures (duplicate C524A cultures in CD-Hyrbidoma medium and CDM medium) ranged between 20-35 hours ( Figure 6b), and cell viabilities were consistently between eighty-five to ninety percent between passages 2 and 11 ( Figure 6a, 6b, 6c). IgG titer at the end of the stability study was eighty-three percent of the beginning culture for C524A in CDM medium, and was greater than ninety percent for C524A in CD-Hyrbidoma medium ( Figure 6d).
  • Example 2 Transfection of C463A cells in CD media with plasmids encoding a human monoclonal antibody (h-mAb).
  • h-mAb heavy chain expression vector is linearized by digestion with an appropriate restriction enzyme and h-mAb light chain expression vector is also linearized using an appropriate restriction enzyme.
  • C463A Prior to the transfection, C463A is thawed in a CD medium and grown for a few passages. Approximately 1 x 10 7 C463A cells are transfected with about lO ⁇ g of the premixed linearized plasmids by electroporation (200 V and 1180 ⁇ F). See Knight et al., 30 MOLECULAR IMMUNOLOGY 1332 (1993).
  • the transfection steps are all conducted using the same CD medium as the one used prior to transfection. Following transfection, the cells are seeded at a viable cell density of 1 x 10 4 cells/well in 96-well tissue culture dishes with a CD medium. After incubating the cells at 37°C, 5% C0 2 for about 40 hours, an equal volume of a CD medium and 2X MHX selection is added. The plates are incubated at 37°C, 5% C0 2 for about two weeks until colonies become visible.
  • Cell supernatants from transfectant colonies are assayed after two weeks using the methods described in Examples 1 and 4.
  • the clones producing the highest amount of IgG as determined by ELISA are transferred to 24-well plates containing a CD medium and expanded for further quantification and comparison of IgG expression levels.
  • independent C463A transfectants are subcloned by seeding an average of one cell per well in 96-well plates.
  • the quantity of antibody produced by the subclones is again determined by assaying supernatants from individual subclone colonies. Optimal subclones are selected for further analysis.
  • Growth curve analyses are performed on selected cell lines grown in CD media as described in Examples 1 and 4 and compared to the selected cell lines and control cell lines grown in optimal medium.
  • stability studies of the selected cell lines grown in CD media are conducted as described in Examples 1 and 4 and compared to the selected cell tines and control cell lines grown in optimal medium.
  • the production of h-mAbs by the selected cell lines grown in a CD medium is comparable to antibody production by control cell lines either grown in optimal medium or transfected and maintained as in Example 1, in terms of quantity and quality.
  • the selected cell lines grown in a CD medium are observed to stably produce h-mAbs at least as long as or longer than control cell tines.
  • Example 3 Commercial-scale culture of C524A for the production of rTNV148B.
  • One vial of C524A cells is removed from liquid nitrogen, and thawed in a sterile 37°C water bath. The cells are then removed, placed into sterile CD medium, and then expanded in spinner flasks at 37°C. After standard quality assays, and further expansion, cell cultures are pooled and introduced aseptically into a sterile, 500 titer or 1,000 liter bioreactor. A sterile CD medium is added to the bioreactor to the final desired volume, and the bioreactor system engaged for rTNV148B production.
  • the bioreactor system is preferably a continous perfusion system, in which product- containing media is sieved by a spin filter, and harvested from the cell-containing retentate.
  • Fresh sterile CD medium is replenished into the bioreactor to maintain nearly constant volume in the reactor vessel.
  • Temperature, dissolved oxygen, pH, and cell density are monitored. Cell density and viability is observed throughout the production ran, which is terminated when the cells have undergone the maximum doublings allowed by regulatory authorities, or when viability drops below twenty percent.
  • the rTNV148B product may be purified by methods known in the art. Yield of rTNV148B averages from about 50 ⁇ g/ml to about 120 ⁇ g/ml.
  • hIL-12 mAb (hIL-12 mAb), to produce the C463A-derived, hIL-12 mAb production cell line.
  • Heavy chain expression vector is linearized by digestion with an appropriate restriction enzyme and tight chain expression vector is also linearized using an appropriate restriction enzyme.
  • C463A cells are transfected with about lO ⁇ g of the premixed linearized plasmids by electroporation and cells cultured and transfectants selected as described in Example 1. Cell supernatants from transfectant colonies are assayed approximately two weeks later for human IgG (i.e., hIL-12 mAb). Briefly, cell supernatants are incubated on 96-well ELISA plates that are coated with goat antibodies specific for the Fc portion of human IgG. Human IgG bound to the coated plates is detected using alkaline phosphatase-conjugated goat anti-human IgG (heavy chain + light chain) antibody and alkaline phosphatase substrates as described.
  • cell supernatants from the parental lines Prior to subcloning the selected cell lines, cell supernatants from the parental lines are used to test the antigen binding characteristics of hIL-12 mAb.
  • concentrations of hIL-12 mAb in the cell supernatant samples are first determined by ELISA. Titrating amounts of the supernatant samples, or purified hIL-12 mAb positive control, are then incubated in 96-well plates coated with 2 ⁇ g/ml of human IL-12. Bound mAb is then detected with alkaline phosphatase-conjugated goat anti-human IgG (heavy chain + light chain) antibody and the appropriate alkaline phosphatase substrates.
  • ML- 12 mAb produced in C463A cells is preferably observed to bind specifically to human IL-12 in a manner indistinguishable from the purified hIL-12 mAb. Characterization of selected cell lines
  • Growth curve analyses are performed on selected cell lines by seeding T-75 flasks with a starting cell density of 2 x 10 5 vc/ml in IMDM, 5% FBS or CD media. Cell number and hIL-12 mAb concentration are monitored on a daily basis until the cultures are spent. Sp 2/ o parental cells transfected with hIL-12 mAb are grown in EVIDM, 5% FBS as a control and growth curve analyses are performed. hIL-12 mAb production by the selected cell lines grown in a CD medium is preferably observed to be equal or superior to ML- 12 mAb production by Sp 2/0 parental cells transfected with ML- 12 mAb and grown in optimal medium. Moreover, ML- 12 mAb production by the selected cell lines grown in a CD medium is preferably observed to be equal to or higher than ML-12 mAb production by the selected cell lines grown in optimal growth medium.
  • the stability of ML- 12 mAb production over time for the selected cell tines is assessed by culturing cells in 24-well dishes with CD media or optimal growth medium for varying periods of time.
  • the production of ML-12 mAb by selected cell lines is also compared to production by Sp /0 parental cells transfected with ML-12 mAb and grown in optimal medium.
  • ML- 12 mAb production by the selected cell lines grown in a CD medium is comparable to ML-12 mAb production by Sp 2/ o parental cells transfected with ML-12 mAb and grown in optimal medium, in terms of quality and quantity.
  • selected cell lines grown in a CD medium are stably produce ML-12 mAb for a term comparable to that of Sp / o parental cells transfected with ML-12 mAb and grown in optimal medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte: sur des lignées de cellules clonales de myélomes pouvant croître continuellement dans un milieu défini chimiquement; sur la production de protéines dans des lignées cellules clonales de myélomes et toute lignée en dérivant; sur des procédés d'identification de lignées de cellules pouvant croître dans un milieu défini chimiquement; et sur des méthodes commerciales permettant de fournir à des clients les cellules, lignées de cellules et cultures de cellules de la présente invention.
PCT/US2002/039496 2001-12-14 2002-12-11 Lignees de cellules clonales de myelomes utilisables pour la production de proteines dans un milieu defini chimiquement WO2003052064A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003552931A JP2005512538A (ja) 2001-12-14 2002-12-11 無血清培地中でタンパク質を製造するのに有用なクローン性骨髄腫細胞系
CA002470026A CA2470026A1 (fr) 2001-12-14 2002-12-11 Lignees de cellules clonales de myelomes utilisables pour la production de proteines dans un milieu defini chimiquement
AU2002362130A AU2002362130A1 (en) 2001-12-14 2002-12-11 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
EP02797264A EP1490481A4 (fr) 2001-12-14 2002-12-11 Lignees de cellules clonales de myelomes utilisables pour la production de proteines dans un milieu defini chimiquement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33942901P 2001-12-14 2001-12-14
US60/339,429 2001-12-14

Publications (2)

Publication Number Publication Date
WO2003052064A2 true WO2003052064A2 (fr) 2003-06-26
WO2003052064A3 WO2003052064A3 (fr) 2004-10-28

Family

ID=23328968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039496 WO2003052064A2 (fr) 2001-12-14 2002-12-11 Lignees de cellules clonales de myelomes utilisables pour la production de proteines dans un milieu defini chimiquement

Country Status (5)

Country Link
EP (1) EP1490481A4 (fr)
JP (1) JP2005512538A (fr)
AU (1) AU2002362130A1 (fr)
CA (1) CA2470026A1 (fr)
WO (1) WO2003052064A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083060A1 (fr) * 2004-03-01 2005-09-09 Kitakyushu Foundation For The Advancement Of Industry, Science And Technology Lignées de cellules humaines servant à la production d'une protéine, fournies en choisissant des lignées ayant une teneur élevée en protéines intracellulaires et en les mutant avec des produits cancerigènes
JP2008507300A (ja) * 2004-07-23 2008-03-13 イムノメディクス， インコーポレイテッド 細胞培養物の寿命および由来するタンパク質の収率を増加させるための方法および組成物
JP2013172722A (ja) * 2005-07-25 2013-09-05 Immunomedics Inc 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物
US10736948B2 (en) 2013-03-15 2020-08-11 In3Bio Ltd. Epidermal growth factor fusion proteins with mutant cholera toxin B subunits

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484L (fi) * 1982-05-05 1983-11-06 Genentech Inc Plasminogen aktivator foer maenskovaevnad
EP0112809B1 (fr) * 1982-12-21 1986-05-28 Ferring AB Dérivés de vasotocine
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5677275A (en) * 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
WO1997029765A1 (fr) * 1996-02-16 1997-08-21 The Regents Of The University Of California Peptides antimicrobiens et procedes d'utilisation associes
US6075123A (en) * 1996-06-03 2000-06-13 St. Jude Children's Research Hospital Cyclin-C variants, and diagnostic and therapeutic uses thereof
DE60230858D1 (de) * 2001-02-15 2009-03-05 Centocor Inc Chemisch definiertes medium für kultivierte säugerzellen

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083060A1 (fr) * 2004-03-01 2005-09-09 Kitakyushu Foundation For The Advancement Of Industry, Science And Technology Lignées de cellules humaines servant à la production d'une protéine, fournies en choisissant des lignées ayant une teneur élevée en protéines intracellulaires et en les mutant avec des produits cancerigènes
GB2426523A (en) * 2004-03-01 2006-11-29 Kitakyushu Foundation Human cell strains for protein production,provided by selecting strains with high intracellular protein and mutating with carcinogens
JP2007535298A (ja) * 2004-03-01 2007-12-06 財団法人北九州産業学術推進機構 タンパク質産生新規ヒト細胞株、新規ヒト細胞株の選択方法、新規ヒト細胞株の使用、それらからのタンパク質産生方法及び精製方法、及び新規ヒト細胞株を利用した薬学組成物
GB2426523B (en) * 2004-03-01 2008-10-22 Kitakyushu Foundation Human cell strains for protein production,provided by selecting strains with high intracellular protein and mutating with carcinogens
US7678570B2 (en) 2004-03-01 2010-03-16 Kitakyushu Foundation For The Advancement Of Industry, Science And Technology Human cell strains for protein production, provided by selecting strains with high intracellular protein and mutating with carcinogens
JP4849408B2 (ja) * 2004-03-01 2012-01-11 財団法人北九州産業学術推進機構 タンパク質産生新規ヒト細胞株、新規ヒト細胞株の選択方法、新規ヒト細胞株の使用、それらからのタンパク質産生方法及び精製方法、及び新規ヒト細胞株を利用した薬学組成物
JP2008507300A (ja) * 2004-07-23 2008-03-13 イムノメディクス， インコーポレイテッド 細胞培養物の寿命および由来するタンパク質の収率を増加させるための方法および組成物
JP2012254084A (ja) * 2004-07-23 2012-12-27 Immunomedics Inc 細胞培養物の寿命および由来するタンパク質の収率を増加させるための方法および組成物
JP2013172722A (ja) * 2005-07-25 2013-09-05 Immunomedics Inc 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物
US10736948B2 (en) 2013-03-15 2020-08-11 In3Bio Ltd. Epidermal growth factor fusion proteins with mutant cholera toxin B subunits
US11419923B2 (en) 2013-03-15 2022-08-23 In3Bio Ltd. Self-assembling synthetic proteins

Also Published As

Publication number Publication date
EP1490481A2 (fr) 2004-12-29
WO2003052064A3 (fr) 2004-10-28
CA2470026A1 (fr) 2003-06-26
AU2002362130A1 (en) 2003-06-30
EP1490481A4 (fr) 2005-12-07
JP2005512538A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
US9128090B2 (en) Rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
US20030211078A1 (en) Pseudo-antibody constructs
EP0931162A1 (fr) Production de proteine multimere par procede de fusion cellulaire
MXPA04005190A (es) Proceso para cultivo de celulas.
CN101735981B (zh) 制备细胞毒性淋巴细胞的方法
EP2137320A1 (fr) Clones à expression élevée de cellules mammifères avec une protéine fluorescente a ou g
Chuck et al. Population balance between producing and nonproducing hybridoma clones is very sensitive to serum level, state of inoculum, and medium composition
Kruisbeek Production of mouse T cell hybridomas
Walsh et al. Dexamethasone inhibits prolonged survival and autocrine granulocyte-macrophage colony-stimulating factor production by human eosinophils cultured on laminin or tissue fibronectin
US20040185506A1 (en) Epitope mapping using nuclear magnetic resonance
WO2003052064A2 (fr) Lignees de cellules clonales de myelomes utilisables pour la production de proteines dans un milieu defini chimiquement
JP2009505666A (ja) 完全ヒトハイブリドーマ融合パートナー細胞株
WO2004053080A2 (fr) Lignees cellulaires clonales de myelome utiles a la fabrication de proteines dans des milieux chimiquement definis
WO2003051720A2 (fr) Lignee cellulaire myelomateuse utile a la production de proteines recombinantes dans des milieux chimiquement definis
Whiteside Measurement of cytotoxic activity of NK/LAK cells
US20040152170A1 (en) Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
WO2003091700A2 (fr) Cartographie d'epitopes faisant appel a la resonance magnetique nucleaire
Hnasko et al. A bioassay for optimization of macrophage-conditioned medium as a culture supplement to promote hybridoma cell survival and growth
US20220243222A1 (en) Vectors and expression systems for producing recombinant proteins
Gupta et al. Expression and localization of tissue factor-based procoagulant activity (PCA) in pigeon monocyte-derived macrophages
Nishimune et al. Isolation of mutants showing temperature-sensitive cell growth from embryonal carcinoma cells: Control of stem cell differentiation by incubation temperatures
CN109504661B (zh) 一种抗原特异性的t淋巴细胞杂交瘤及其制备方法和应用
Harriman Measurement of mouse and human interleukin 5
CN102827274B (zh) 一种乙肝疫苗抗体及含该抗体的芯片
SK281965B6 (sk) Monoklonálna protilátka inhibujúca zachytávanie krvotvorných kmeňových buniek a hybridóm

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002362130

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2470026

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003552931

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002797264

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002797264

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载